NCT05565690

Brief Summary

Aim of the study is evaluation of accuracy of magnetic resonance spectroscopy in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasm

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
64

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Oct 2022

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2022

Completed
1 day until next milestone

Study Start

First participant enrolled

October 1, 2022

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 4, 2022

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2024

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

October 4, 2022

Status Verified

September 1, 2022

Enrollment Period

2 years

First QC Date

September 30, 2022

Last Update Submit

September 30, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • evaluation of accuracy of magnetic resonance spectroscopy in differentiation between neoplastic and non neoplastic lesions and determination the type of neoplasm

    Analysis of the MRS metabolites peaks and test if they can differentiate between neoplastic and non neoplastic lesions and grades of neoplasm by comparison with postoperative histopathology

    Baseline

Interventions

MRSDEVICE

It is a tool used to determine the molecular structure of compounds or to detect the compound presence , it provides metabolic information from living brain

Eligibility Criteria

Sexall
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with brain lesions of any age

You may qualify if:

  • patients with solitary intraaxial brain lesions
  • patients with de novo lesions
  • Patient age : any age

You may not qualify if:

  • patients with multiple intra-axial brain lesions
  • patients with extra-axial brain lesions
  • patients with recurrent lesions
  • patients receiving chemotherapy or radiotherapy
  • patients unfit for surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Melkersson-Rosenthal Syndrome

Condition Hierarchy (Ancestors)

Facial Nerve DiseasesMouth DiseasesStomatognathic DiseasesCranial Nerve DiseasesNervous System Diseases

Study Officials

  • Ali Ahmed Abd-Elaleem, Lecturer

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Ahmed Mohamed Aboelmagd, Resident doctor

CONTACT

Mohamed El-Sayed Mahmoud, Professor

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Resident doctor

Study Record Dates

First Submitted

September 30, 2022

First Posted

October 4, 2022

Study Start

October 1, 2022

Primary Completion

October 1, 2024

Study Completion

November 1, 2024

Last Updated

October 4, 2022

Record last verified: 2022-09